GLP-1/Weight Loss

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

With its foundational drug a success, Madrigal bets billions on next-gen siRNA tech, aiming to fuse it with Rezdiffra and dominate MASH treatment.

Pharma veteran Pinder Sahota joins digital health firm Reset Health, signaling a strategic shift to integrated care in the new era of weight-loss drugs.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

New Medicare rules expand access to opioid alternatives, reshaping post-surgery recovery and rewarding companies at the forefront of pain management.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.